{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:12:28Z","timestamp":1770837148367,"version":"3.50.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1136\/ard-2023-225054","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T18:21:03Z","timestamp":1700590863000},"page":"e3-e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Response to: Correspondence on \u20182023 ACR\/EULAR antiphospholipid syndrome classification criteria\u2019 by Miro-Mur et al"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-677X","authenticated-orcid":false,"given":"Doruk","family":"Erkan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-7696","authenticated-orcid":false,"given":"Medha","family":"Barbhaiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9326-6881","authenticated-orcid":false,"given":"Stephane","family":"Zuily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Bertolaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Willis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"Devreese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-225054_bib1","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1136\/ard-2023-225042","article-title":"Correspondence on \u20182023 ACR\/EULAR antiphospholipid syndrome classification criteria' by Barbhaiya et al","volume":"83","author":"Miro-Mur","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225054_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225054_bib3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225054_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.15585","article-title":"Semiquantitative interpretation of Anticardiolipin and Anti\u03b22Glycoprotein I antibodies measured with various Analytical platforms: communication from the ISTH SSC subcommittee on Lupusanticoagulant\/Antiphospholipid antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1136\/ard-2023-225054_bib5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1055\/s-0039-1679901","article-title":"Detection of anti-Cardiolipin and anti-\u03b22Glycoprotein I antibodies differs between platforms without influence on association with clinical symptoms","volume":"119","author":"Chayoua","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1136\/ard-2023-225054_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11926-021-01034-6","article-title":"Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-year update","volume":"23","author":"Erkan","year":"2021","journal-title":"Curr Rheumatol Rep"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672400373X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672400373X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-225054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:19:49Z","timestamp":1749806389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672400373X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S000349672400373X"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-225054","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to: Correspondence on \u20182023 ACR\/EULAR antiphospholipid syndrome classification criteria\u2019 by Miro-Mur et al","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225042","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}